Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.23.3
Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 1,901 $ 622 $ 6,597 $ 2,196
General and administrative 3,639 2,953 7,664 12,785
Change in fair value of warrants and derivatives (3,587) 0 (717) (7)
Change in contingent consideration valuation (177) 0 (35) 0
Total operating expenses 1,776 3,575 13,509 14,974
Operating loss from continuing operations (1,776) (3,575) (13,509) (14,974)
Other expense:        
Other expense, net (115) (512) (3,069) (1,652)
Net loss from continuing operations (1,891) (4,087) (16,578) (16,626)
Income (loss) on discontinued operation (43) (25,120) 18,673 (32,920)
Net income (loss) $ (1,934) $ (29,207) $ 2,095 $ (49,546)
Per share information:        
Net loss per share from continuing operations, basic $ (0.29) $ (13.81) $ (3.36) $ (86.53)
Net loss per share from continuing operations, diluted (0.29) (13.81) (3.36) (86.53)
Net income (loss) per share from discontinued operations, basic (0.01) (84.89) 3.69 (171.34)
Net income (loss) per share from discontinued operations, diluted (0.01) (84.89) 3.69 (171.34)
Net income (loss) per share, basic (0.3) (98.7) 0.33 (257.87)
Net income (loss) per share, diluted $ (0.3) $ (98.7) $ 0.33 $ (257.87)
Weighted average common shares outstanding, basic 7,993,522 295,903 5,065,759 192,135
Weighted average common shares outstanding, diluted 7,993,522 295,903 5,065,759 192,135